About the Lab
Under the direction of Hyun-Sung Lee, M.D., Ph.D., the Systems Onco-Immunology Laboratory (SOIL) applies innovative multi-omics methodologies to elucidate cancer-immune networks and to investigate novel immunotherapy approaches. The SOIL was founded in 2015 by Dr. David J. Sugarbaker, a visionary in thoracic surgery and thoracic oncology. The name “SOIL” derives from the “Seed and Soil” theory of metastasis, which formed the conceptual foundation for our early collaborative work with Dr. Sugarbaker. Our laboratory focuses on translational thoracic oncology and engages broadly in scientific collaboration and education within the field of systems onco-immunology.
Lab Projects
Single-cell multi-omics integration to exploit autoimmunity induced by checkpoint immunotherapy in malignant pleural mesothelioma
We aim to define autoimmune susceptibility and elucidate novel cellular and molecular mechanisms underlying immunotoxicity following immune checkpoint therapy in pleural mesothelioma.
Unraveling NK-like CD8 T cell dynamics for advancing precision immunotherapy
We aim to elucidate the mechanisms of immune-related adverse events (irAEs) by investigating the intersection between anti-tumor immunity and autoimmunity and to develop preclinical therapeutic strategies for their effective management.
Proteomic determinants of response to checkpoint blockade in malignant pleural Mesothelioma
We aim to investigate the immunoproteogenomic determinants that predict responses to checkpoint blockade in pleural mesothelioma.
Publications
Jang HJ, Patel M, Wang DY, Kang SW, Choi JM, Lee C, Vilchis M, Shim JS, Mitra S, Ranchod P, Kuncheria A, Hudson W, Jindra P, Lenge De Rosen V, Ramineni M, Camp ER, Kheradmand F, Ripley RT, Groth SS, Lee HS, Burt BM (2025). Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma. Clin Cancer Res, 31(13):2639-2654. PMID: 40208070.
Espinosa-Carrasco G, Chiu E, Scrivo A, Zumbo P, Dave A, Betel D, Kang SW, Jang HJ, Hellmann M, Burt BM, Lee HS, Schietinger A. (2024) Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell, 42(7):1202-1216. PMID: 38906155.
Lee HS, Jang HJ, Ramineni M, Wang DY, Ramos D, Choi JM, Splawn T, Espinoza M, Almarez M, Hosey L, Jo E, Hilsenbeck SG, Amos CI, Ripley RT, Burt BM. (2023). A phase II window of opportunity study of neoadjuvant PD-L1 versus PD-L1 plus CTLA4 blockade for patients with malignant pleural mesothelioma. Clin Cancer Res, 29(3):548-559, PMID: 36469573. “Cover image in Feb issue, 2023”
Jang HJ, Lee HS, Yu W, Ramineni M, Truong CY, Ramos D, Splawn TG, Choi JM, Jung SY, Lee JS, Wang DY, Sederstrom JM, Pietropaolo M, Kheradmand F, Amos CI, Wheeler TM, Ripley RT, Burt BM. (2022). Therapeutic targeting of macrophage plasticity remodels the tumor-immune microenvironment. Cancer Res, 82(14):2593-2609. PMID: 35709756. “Cover image in July issue, 2022”